How many subsidiaries does Autolus Therapeutics plc file with the SEC?

5, listed in its most recent exhibit 21. They are incorporated across 4 jurisdictions (England and Wales, Delaware, Germany, Switzerland). That exhibit is filed with the company's annual report and is the company's own list, not an estimate.

Is Autolus Therapeutics plc financially healthy?

Autolus Therapeutics plc scores 2 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of Autolus Therapeutics plc?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are RENAISSANCE TECHNOLOGIES LLC (trimming), BANK OF AMERICA CORP /DE/ (trimming), BlackRock, Inc. (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

Autolus Therapeutics plc (AUTL)

Nasdaq · ADR · Biological Products, (No Diagnostic Substances)

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

company in London, United Kingdom

Corporate structure

5 entities across 4 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-03-27 — see the exhibit.

Which other public companies file entities in the same places:

England and Wales2 Delaware1 Germany1 Switzerland1

Subsidiaries of Autolus Therapeutics plc as disclosed in its SEC filing
Entity	Jurisdiction	Note
Autolus Holdings (UK) Limited	England and Wales
Autolus Limited	England and Wales
Autolus Inc.	Delaware
Autolus GmbH	Germany
Autolus Switzerland AG	Switzerland

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

2 / 7

FAILReturn on assets positiveROA -48.8%
FAILOperating cash flow positiveOCF -284M
FAILReturn on assets improving-28.2% → -48.8%
PASSCash flow exceeds earningsOCF -284M vs NI -288M
FAILLong-term debt ratio fallingno debt reported
FAILCurrent ratio improving10.88 → 5.94
FAILNo share dilution255M → 266M shares
FAILGross margin improvingno gross profit reported
PASSAsset turnover improving0.01× → 0.13×

Altman Z-score

-3.24distress

Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2023	—	—	—	—	—
FY2023	—	—	—	—	—
FY2023	—	—	—	—	—
FY2023	$1.7M	−$208.4M	−$156.6M	—	173,941,926
FY2024	$10.1M	−$220.7M	−$228.3M	—	255,161,038
FY2025	$75.4M

Ownership flow

9 institutions tracked — 5 added, 4 reduced. Index money added 136,951 shares while active managers cut 393,303.

Institutional holders of Autolus Therapeutics plc and their share-count change
Manager	Kind	Shares	Change	Value
Point72 Asset Management, L.P.	Hedge fund	71,227	−355,756	$113,963
MORGAN STANLEY	Active fund	1,260,832	+319,009	$2.0M
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	1,984,700	−314,799	$3.2M
BANK OF AMERICA CORP /DE/	Active fund	1,605,092

Identity

CIK: 0001730463
LEI: 549300C0KZP8EYROLL02
FIGI: BBG00KVT05R6
SIC: 2836 · Biological Products, (No Diagnostic Substances)
Incorporated: United Kingdom
Headquarters: LONDON, United Kingdom
Founded: 2014-01-01

Ownership

Institutional: 63.4%
Institutions: 100
Insiders: 18.1%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Questions about Autolus Therapeutics plc

How many subsidiaries does Autolus Therapeutics plc file with the SEC?: 5, listed in its most recent exhibit 21. They are incorporated across 4 jurisdictions (England and Wales, Delaware, Germany, Switzerland). That exhibit is filed with the company's annual report and is the company's own list, not an estimate.
Is Autolus Therapeutics plc financially healthy?: Autolus Therapeutics plc scores 2 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of Autolus Therapeutics plc?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are RENAISSANCE TECHNOLOGIES LLC (trimming), BANK OF AMERICA CORP /DE/ (trimming), BlackRock, Inc. (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.